Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Humanitas Mirasole S.p.A.
Sponsor

Humanitas Mirasole S.p.A.

Italy Via Alessandro Manzoni 56, 20089 Rozzano, Italy

About the sponsor

Humanitas Mirasole S.p.A. supports clinical research in diffuse large B-cell lymphoma, high-grade B-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome, with additional work in recurrent metastatic nasopharyngeal carcinoma and hepatocellular carcinoma. The portfolio includes interest in disease settings that are refractory, relapsed, or resistant to prior treatment.

  • Relapsed/refractory lymphoma after CAR T-cell therapy
  • Acute myeloid leukemia and myelodysplastic syndrome
  • Nasopharyngeal carcinoma
  • Hepatocellular carcinoma

Research activity in this area reflects a strong focus on difficult-to-treat malignancies and post-treatment disease control.

About Specializations

Humanitas Mirasole S.p.A. runs clinical trials in conditions such as Acute myocardial infarction, Diabetes mellitus, Nasopharyngeal cancer, Head and neck cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

8 clinical trials

Acute myocardial infarction+1

Recruiting

Sodium-glucose cotransporter-2 inhibitor drug combination for patients with diabetes and heart attack to slow coronary artery disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Humanitas Mirasole S.p.A.

Nasopharyngeal cancer

Recruiting

Study of toripalimab, cisplatin and gemcitabine combination as first treatment for patients with recurrent or metastatic nasopharyngeal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Humanitas Mirasole S.p.A.

Head and neck cancer

Recruiting

Study of Mitazalimab Injection Treatment for Patients with High-Risk Oral Potentially Malignant Disorders

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mitazalimab
  • Sponsor:Humanitas Mirasole S.p.A.

Adenocarcinoma gastric+3

Not yet recruiting

Study of immune response and biomarkers in patients with metastatic solid tumors treated with BMS-986340 and nivolumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Humanitas Mirasole S.p.A.

Acute myeloid leukaemia

Not recruiting

Study of Monalizumab for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Haploidentical Transplantation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Monalizumab
  • Sponsor:Humanitas Mirasole S.p.A.

Rheumatoid arthritis

Not recruiting

Study on Monitoring Adalimumab for Maintaining Disease Control in Adults with Rheumatoid Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Diakonhjemmet Sykehus AS

B-cell lymphoma

Not recruiting

Study of Loncastuximab Tesirine for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma After CAR T-Cell Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Loncastuximab Tesirine
  • Sponsor:Humanitas Mirasole S.p.A.

Hepatocellular carcinoma

Not recruiting

Study on Cabozantinib for Patients with Liver Cancer Not Responding to Previous Immune Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Humanitas Mirasole S.p.A.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.